IR@PKUHSC  > 北京大学第三临床医学院  > 内分泌科
学科主题内分泌
超重或肥胖2型糖尿病患者的注射降糖治疗策略
其他题名Injectable treatment strategy of type 2 diabetes in overweight or obese patients
洪天配
关键词糖尿病, 2型 胰高血糖素样肽-1 注射剂 diabetes mellitus,type 2 glucagon-like peptide-1 injection
刊名临床药物治疗杂志
2015
DOI10.3969/j.issn.1672-3384.2015.05.001
5页:1-5
收录类别中国科技核心期刊
文章类型Journal Article
摘要随着自然病程的进展,2型糖尿病患者常需进行起始注射降糖治疗。对于超重或肥胖的2型糖尿病患者,选择注射降糖治疗时常会面临诸多的挑战。与胰岛素相比,胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂有相似的降糖疗效,且可显著减轻体重,改善胰岛素抵抗,保护胰岛β细胞功能,降低血压,改善血脂异常及非酒精性脂肪性肝病等。因此,在超重或肥胖的2型糖尿病患者中,GLP-1受体激动剂具有改善多重代谢异常的综合益处。 Type 2 diabetes is a progressive disease. Initial injectable therapy may be required over the disease course. There have been multiple challenges in the management of injectable treatment for overweight or obese patients with type 2 diabetes. Compared to insulin, GLP-1 receptor agonists not only have similar efifcacy on glycemic control, but also result in signiifcant weight loss as well as beneifts to insulin resistance, β cell function, blood pressure, dyslipidemia and non-alcoholic fatty liver disease, etc. Thus, GLP-1 receptor agonists could be a good candidate for comprehensive therapy for overweight or obese patients with type 2 diabetes.
语种中文
原文出处查看原文
Citation statistics
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/72894
Collection北京大学第三临床医学院_内分泌科
作者单位北京大学第三医院内分泌科,北京,100191
Recommended Citation
GB/T 7714
洪天配. 超重或肥胖2型糖尿病患者的注射降糖治疗策略[J]. 临床药物治疗杂志,2015(5):1-5.
APA 洪天配.(2015).超重或肥胖2型糖尿病患者的注射降糖治疗策略.临床药物治疗杂志(5),1-5.
MLA 洪天配."超重或肥胖2型糖尿病患者的注射降糖治疗策略".临床药物治疗杂志 .5(2015):1-5.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[洪天配]'s Articles
百度学术
百度学术Similar articles in
[洪天配]'s Articles
必应学术
必应学术Similar articles in
[洪天配]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.